ZIVE developed a chest-worn ECG device (developed 2018–2020) that streams detailed heart-rate data in real time to a smartphone or tablet for use at home or in medical settings. The device is lightweight and intended for regular, long-term monitoring during rest, exercise, or daily activities. ZIVE’s ECG device is CE-certified for sale across the European Union. The company plans to develop AI- and machine-learning-based software to analyze stored cardiogram data, present conclusions, and extend device functionality. Management says the software enabling historical data storage and long-term analysis is important for detecting and preventing heart problems, and they aim to complete development in 2022. ZIVE previously donated 10 devices to Lithuanian hospitals for remote monitoring of COVID-19 patients.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

May 2021